In the last trading session, 16.96 million shares of the TransCode Therapeutics Inc (NASDAQ:RNAZ) were traded, and its beta was 1.30. Most recently the company’s share price was $0.69, and it changed around -$0.43 or -38.15% from the last close, which brings the market valuation of the company to $0.48M. RNAZ currently trades at a discount to its 52-week high of $66.33, offering almost -9513.04% off that amount. The share price’s 52-week low was $0.64, which indicates that the current value has risen by an impressive 7.25% since then. We note from TransCode Therapeutics Inc’s average daily trading volume that its 10-day average is 27.66 million shares, with the 3-month average coming to 6.17 million.
TransCode Therapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended RNAZ as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. TransCode Therapeutics Inc is expected to report earnings per share of -3.21 for the current quarter.
TransCode Therapeutics Inc (NASDAQ:RNAZ) trade information
Instantly RNAZ has showed a red trend with a performance of -38.15% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.6700 on recent trading dayincreased the stock’s daily price by 58.68%. The company’s shares are currently down -79.45% year-to-date, but still down -11.19% over the last five days. On the other hand, TransCode Therapeutics Inc (NASDAQ:RNAZ) is -91.42% down in the 30-day period. We can see from the shorts that 0.54 million shares have been sold at a short interest cover period of 0.16 day(s).
TransCode Therapeutics Inc (RNAZ) estimates and forecasts
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of 300k in revenue for the current quarter. Forecasts for the next quarter put sales growth at 0.00%. Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -28.81%. TransCode Therapeutics Inc earnings are expected to increase by 95.41% in 2025, but the outlook is positive 78.85% per year for the next five years.
TransCode Therapeutics Inc (NASDAQ:RNAZ)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 5.03% of TransCode Therapeutics Inc shares, and 22.36% of them are in the hands of institutional investors. The stock currently has a share float of 23.55%.
Fidelity Extended Market Index Fund and Fidelity Total Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.86 shares worth $1983.0, making up 0.41% of all outstanding shares. On the other hand, Fidelity Total Market Index Fund held roughly 1.18 shares worth around $816.0, which represents about 0.17% of the total shares outstanding.
